DE60335810D1 - Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung - Google Patents

Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung

Info

Publication number
DE60335810D1
DE60335810D1 DE60335810T DE60335810T DE60335810D1 DE 60335810 D1 DE60335810 D1 DE 60335810D1 DE 60335810 T DE60335810 T DE 60335810T DE 60335810 T DE60335810 T DE 60335810T DE 60335810 D1 DE60335810 D1 DE 60335810D1
Authority
DE
Germany
Prior art keywords
expression
citrate lyase
atp citrate
inhibiting
medical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335810T
Other languages
English (en)
Inventor
Yoshiro Kitahara
Tomohisa Okutsu
Akira Mitsui
Akira Okano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of DE60335810D1 publication Critical patent/DE60335810D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
DE60335810T 2002-05-28 2003-05-28 Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung Expired - Lifetime DE60335810D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002154397 2002-05-28
PCT/JP2003/006651 WO2003099332A1 (fr) 2002-05-28 2003-05-28 Composition medicinale pour inhiber l'expression d'atp-citrate lyase et son utilisation

Publications (1)

Publication Number Publication Date
DE60335810D1 true DE60335810D1 (de) 2011-03-03

Family

ID=29561357

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335810T Expired - Lifetime DE60335810D1 (de) 2002-05-28 2003-05-28 Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung

Country Status (12)

Country Link
EP (1) EP1547614B1 (de)
JP (1) JP4433496B2 (de)
KR (1) KR100983990B1 (de)
AT (1) ATE495740T1 (de)
AU (1) AU2003241823A1 (de)
CY (1) CY1111443T1 (de)
DE (1) DE60335810D1 (de)
DK (1) DK1547614T3 (de)
ES (1) ES2359910T3 (de)
PT (1) PT1547614E (de)
SI (1) SI1547614T1 (de)
WO (1) WO2003099332A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707670A2 (pt) 2006-02-08 2011-05-10 Kurume University E Ajinomoto Co Inc composiÇço farmacÊutica, e, uso de um composto meglitinida
WO2010119873A2 (ja) * 2009-04-13 2010-10-21 株式会社資生堂 皮下脂肪増加抑制による皮膚の弾性特性の低下の防止方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5447954A (en) * 1992-05-05 1995-09-05 Smithkline Beecham P.L.C. Phenylderivate as inhibitors of ATP citrate lyase
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
EP1218015A2 (de) * 1999-10-08 2002-07-03 Novartis AG Zusammensetzung welche nateglinide and eine andere antidiabetische verbindung enthält
AU1303201A (en) * 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Alkoxyiminoalkanoic acid derivatives
WO2001068136A1 (fr) * 2000-03-17 2001-09-20 Ajinomoto Co., Inc. Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments

Also Published As

Publication number Publication date
KR100983990B1 (ko) 2010-09-30
DK1547614T3 (da) 2011-04-04
KR20050008745A (ko) 2005-01-21
JPWO2003099332A1 (ja) 2005-09-22
AU2003241823A1 (en) 2003-12-12
CY1111443T1 (el) 2015-08-05
ES2359910T3 (es) 2011-05-30
ATE495740T1 (de) 2011-02-15
PT1547614E (pt) 2011-04-06
EP1547614A4 (de) 2007-09-05
EP1547614B1 (de) 2011-01-19
EP1547614A1 (de) 2005-06-29
JP4433496B2 (ja) 2010-03-17
WO2003099332A1 (fr) 2003-12-04
SI1547614T1 (sl) 2011-04-29

Similar Documents

Publication Publication Date Title
MA33720B1 (fr) Inhibiteurs peptiques cycliques de la replication du virus de l&#39;hépatite c
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
EA200701123A1 (ru) Способ очистки транс-(-)-δ-тетрагидроканнабинола и транс-(+)-δ-тетрагидроканнобинола
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
IS8395A (is) Fjölvasýklískar karboxýlsýrur og asýlsúlfónamíð sem hindrar á lifrabólgu C eftirmyndun
SG10201908757TA (en) Boronic acids and esters as inhibitors of fatty amide hydrolase
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
EA201170969A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
BRPI0518315A2 (pt) compostos de tiazol que modulam a atividade da proteÍna hsp90, mÉtodos de inibiÇço, tratamento e induÇço associados e composiÇço farmacÊutica
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
DE60135647D1 (de) Zusammensetzungen zur normalisierung des zirkadianen rythmus
BRPI0607536A2 (pt) tratamento de dor
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
EP2257161A4 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
BRPI0508232A (pt) sìntese de epotilonas, intermediários das mesmas, análogos e usos das mesmas
CO6612211A2 (es) Derivado de amida que tiene una acción hipoglucémica y/o una acción protectora de células b o pancreas
DE60335810D1 (de) Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung
TW200628167A (en) Composition for preventing and/or treating metabolic syndrome and insulin resistance syndrome
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
DE602004028113D1 (de) Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung